Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01324232 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
A Phase 2 study, sponsored by Avanir Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 209
- Enrollment target
NCT01324232 is a Phase 2 study that has completed, run by Avanir Pharmaceuticals. The registered enrollment target is 209 participants.
The verdict
NCT01324232, a Phase 2 study, has completed, sponsored by Avanir Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 209 participants
- Enrollment target
Study Summary
The objectives of the study are to evaluate the safety, tolerability, and efficacy of 3 doses of AVP-923 capsules in the treatment of central neuropathic pain in participants with multiple sclerosis.
Interventions
- DRUG Placebo
- DRUG AVP-923-45
- DRUG AVP-923-30
- DRUG AVP-923-20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 209 participants |
| Start Date | 2011-09-08 |
| Est. Completion | 2013-09-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01324232
The ClinicalTrials.gov registry entry for NCT01324232 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 209 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avanir Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01324232 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01324232 about?
NCT01324232 is a clinical study titled "Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis". The objectives of the study are to evaluate the safety, tolerability, and efficacy of 3 doses of AVP-923 capsules in the treatment of central neuropathic pain in participants with multiple sclerosis.
What is the current status of trial NCT01324232?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 209 participants. The study started on 2011-09-08. Estimated completion is 2013-09-26.
What interventions are being tested in trial NCT01324232?
The interventions under investigation include: Placebo (DRUG), AVP-923-45 (DRUG), AVP-923-30 (DRUG), AVP-923-20 (DRUG).
Who is sponsoring clinical trial NCT01324232?
This trial is sponsored by Avanir Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.